Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -0.27%91 Median PS Value is $3.99 as of Jul. 15, 2026, which is 207% above its 10-year median of 1.30. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 544 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks worse than 52.21% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Birzeit Pharmaceutical Co's Median PS Value or its related term are showing as below:
XPAE:BPC'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.92 Med: 1.3 Max: 1.43
Current: 0.92
During the past 13 years, the highest Price to Median PS Value of Birzeit Pharmaceutical Co was 1.43. The lowest was 0.92. And the median was 1.30.
XPAE:BPC's Price-to-Median-PS-Value is ranked worse than 52.21% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.89
vs XPAE:BPC: 0.92
Birzeit Pharmaceutical Co (XPAE:BPC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Birzeit Pharmaceutical Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.67
/
3.99
=
0.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co Median PS Value Related Terms
Birzeit Pharmaceutical Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:BPC vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.1768.
Birzeit Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.256.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a Median PS Value of $3.99 as of Jul. 15, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Birzeit Pharmaceutical Co and its competitors. This is 207% above median its historical median of 1.30. Over the past decade, Birzeit Pharmaceutical Co's Median PS Value has ranged from 0.92 to 1.43. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #284 out of 544 companies in the Drug Manufacturers industry, placing it in the top 52.2%.
Is Birzeit Pharmaceutical Co's Median PS Value too high?
Birzeit Pharmaceutical Co's current Median PS Value of $3.99 is 207% above median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 1.43. The Drug Manufacturers industry median Median PS Value is 0.89. Birzeit Pharmaceutical Co's value of $3.99 is 348.3% above this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #284 out of 544 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #284 out of 544 companies for Median PS Value. This places Birzeit Pharmaceutical Co in the lower half of its industry. The industry median Median PS Value is 0.89. Birzeit Pharmaceutical Co's value of $3.99 is 348.3% above this benchmark. Historically, Birzeit Pharmaceutical Co's own Median PS Value has ranged from 0.92 to 1.43 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 0.89, Birzeit Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.89, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Median PS Value of $3.99 is 348.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Median PS Value is $3.99, which is 207% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current Median PS Value is $3.99, which is 207% above median its 10-year median of 1.30 and 348.3% above the Drug Manufacturers industry median of 0.89. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Median PS Value is $3.99 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Median PS Value: $3.99 (207% above median its 10-year median of 1.30)
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 348.3% above the Drug Manufacturers median (#284 of 544)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
